Our services
Integrated and delivered by one senior team.
Evidence generation, health economics, statistics and HTA strategy — scoped to the decision you need to support.
01
Literature Review and Evidence Synthesis
We transform clinical data into compelling evidence packages that address HTA requirements across global markets. Our team brings pharma-side experience to evidence synthesis, ensuring your submissions are built on robust, defensible foundations that regulatory and payer bodies accept.
02
Health Economic Modelling
We develop health economic models that translate clinical benefits into economic value, supporting pricing, reimbursement, and strategic decision-making across global and local markets. Our models are built to withstand HTA scrutiny while remaining flexible for scenario planning and market-specific adaptations.
04
Health Technology Assessment
We help you navigate the complex HTA landscape across markets, ensuring your global strategy translates into successful local submissions. Our team has managed HTA submissions from the pharma side, bringing practical insights into what works in practice, not just in theory.
Systematic literature review
Our team can generate robust, high quality literature reviews including:
-
Systematic literature reviews (SLR) for submissions and evidence synthesis
-
Targeted literature reviews (TLR)
-
Rapid literature reviews
Evidence synthesis
Our team has extensive knowledge and experience with evidence synthesis methods including:
-
Indirect treatment comparisons (ITC)
-
Network meta-analysis (NMA)
-
Matching-adjusted indirect comparisons (MIAC)
-
Multi-level network meta-regression
Localisation
Our team has supported many countries globally with localisations and adaptations of HTA deliverables:
-
Adaptation of deliverable reports to suit local requirements
-
Localisation of SLR and evidence synthesis deliverables according to local methodological guidelines
Cost-Effectiveness models
-
Early models
-
Disease agnostic models
-
Cost-effectiveness and cost-utility models (CEM/CUA)
-
Global economic models
-
Technical and strategic model QC and validation
-
Advisory & strategic support with economic modelling
Budget impact and bespoke models
-
Budget impact models (BIM)
-
Cost-per-response models
-
Bespoke models for novel decision problems
-
Interactive value tools and calculators
Model QC, validation and adaptation
-
Technical and strategic model QC
-
Validation of structure, inputs and outputs
-
Deterministic, probabilistic and scenario analyses
-
Adapting global models to local settings
Health economics & outcomes
-
Quality of life analyses
-
Health-state utility values
-
Survival analysis
-
Treatment switching
-
Adverse events
-
Cost inputs
-
Disutility
Post-hoc analysis of clinical trials
-
Post-hoc analysis of clinical trials to support reimbursement dossiers in line with local guidelines
-
Analyses using tailored methodological approaches to support publications
Real world data analysis
-
Cohort definition and study protocol design
-
CPRD, HES and linked national datasets
-
Confounding adjustment and propensity methods
-
External control arms for single-arm trials
-
Missing data and sensitivity analyses
HTA and Submission Strategy
-
Advice on overall HTA & reimbursement submissions strategy
-
Expected HTA & reimbursement outcomes based on planned programme and efficacy/safety profile
-
Identification of risks and mitigation strategies
Trial Design and Evidence Planning
-
Assessment of proposed development programme against competitors & agency expectations
-
Identification of risks, mitigation strategies, and potential changes to development programme to support desired outcomes
Early Evaluation and Decision-Making
-
Assessment of reimbursement potential of early pipeline assets
-
Trade-off assessments for milestone or launch decision
-
Evaluation of business development opportunities